Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer

Aims. To compare hormonal and metabolic profile of type 2 diabetes mellitus patients (T2DM) with or without neoplastic processes with the data from screening for SNPs affecting sensitivity to metformin.To compare the abovementioned parameters including relevant genotype frequency in patients with p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lev Mikhaylovich Bershteyn, Dmitriy Alexeevich Vasil'ev, Aglaya Gennadievna Ievleva, Tatiana Evgen'evna Poroshina, Evgeny Naumovich Imyanitov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	metformin efficacy type 2 diabetes mellitus cancer insulin resistance estradiol single nucleotide polymorphisms Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/0ed7f14609844c7ab76c40242bb98951
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ed7f14609844c7ab76c40242bb98951
record_format	dspace
spelling	oai:doaj.org-article:0ed7f14609844c7ab76c40242bb989512021-11-14T09:00:18ZHormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer2072-03512072-037810.14341/DM2014121-28https://doaj.org/article/0ed7f14609844c7ab76c40242bb989512014-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6326https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aims. To compare hormonal and metabolic profile of type 2 diabetes mellitus patients (T2DM) with or without neoplastic processes with the data from screening for SNPs affecting sensitivity to metformin.To compare the abovementioned parameters including relevant genotype frequency in patients with positive and negative response to metformin.Materials and Methods. A total of 167 patients, all female, aged 43 to 88 years in menopause no shorter than 1 year, with or without history of T2DM were enrolled in this study. 156 patients underwent genetic screening for SNPs that were previously suggested as relevant to metformin efficacy. 55 patients received metformin 1000-1700 g daily with hormonal and metabolic monitoring and assessment of surrogate antineoplastic markers (such as endometrial thickness and mammographic density of mammary glands). Results. There was no unifying hormonal or metabolic phenotype for patients with given metformin-associated SNPs. However, we observed a certain trend for alterations in HOMA-IR and plasma estradiol levels. Dyslipidemia and elevated estradiol levels were positively associated with both types of positive response to metformin ? ?metabolic? and ?antineoplastic? ? though the latter was observed less frequently. Our data suggests that among 8 studied SNPs, the OCT1_R61C genotype (organic cation transporter-1) carriers require more close attention. Conclusion. Larger studies are required for further elucidation of the genetic background for metformin action in patients with various forms of cancer.Lev Mikhaylovich BershteynDmitriy Alexeevich Vasil'evAglaya Gennadievna IevlevaTatiana Evgen'evna PoroshinaEvgeny Naumovich ImyanitovEndocrinology Research Centrearticlemetforminefficacytype 2 diabetes mellituscancerinsulin resistanceestradiolsingle nucleotide polymorphismsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 1, Pp 21-28 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	metformin efficacy type 2 diabetes mellitus cancer insulin resistance estradiol single nucleotide polymorphisms Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	metformin efficacy type 2 diabetes mellitus cancer insulin resistance estradiol single nucleotide polymorphisms Nutritional diseases. Deficiency diseases RC620-627 Lev Mikhaylovich Bershteyn Dmitriy Alexeevich Vasil'ev Aglaya Gennadievna Ievleva Tatiana Evgen'evna Poroshina Evgeny Naumovich Imyanitov Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
description	Aims. To compare hormonal and metabolic profile of type 2 diabetes mellitus patients (T2DM) with or without neoplastic processes with the data from screening for SNPs affecting sensitivity to metformin.To compare the abovementioned parameters including relevant genotype frequency in patients with positive and negative response to metformin.Materials and Methods. A total of 167 patients, all female, aged 43 to 88 years in menopause no shorter than 1 year, with or without history of T2DM were enrolled in this study. 156 patients underwent genetic screening for SNPs that were previously suggested as relevant to metformin efficacy. 55 patients received metformin 1000-1700 g daily with hormonal and metabolic monitoring and assessment of surrogate antineoplastic markers (such as endometrial thickness and mammographic density of mammary glands). Results. There was no unifying hormonal or metabolic phenotype for patients with given metformin-associated SNPs. However, we observed a certain trend for alterations in HOMA-IR and plasma estradiol levels. Dyslipidemia and elevated estradiol levels were positively associated with both types of positive response to metformin ? ?metabolic? and ?antineoplastic? ? though the latter was observed less frequently. Our data suggests that among 8 studied SNPs, the OCT1_R61C genotype (organic cation transporter-1) carriers require more close attention. Conclusion. Larger studies are required for further elucidation of the genetic background for metformin action in patients with various forms of cancer.
format	article
author	Lev Mikhaylovich Bershteyn Dmitriy Alexeevich Vasil'ev Aglaya Gennadievna Ievleva Tatiana Evgen'evna Poroshina Evgeny Naumovich Imyanitov
author_facet	Lev Mikhaylovich Bershteyn Dmitriy Alexeevich Vasil'ev Aglaya Gennadievna Ievleva Tatiana Evgen'evna Poroshina Evgeny Naumovich Imyanitov
author_sort	Lev Mikhaylovich Bershteyn
title	Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
title_short	Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
title_full	Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
title_fullStr	Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
title_full_unstemmed	Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
title_sort	hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/0ed7f14609844c7ab76c40242bb98951
work_keys_str_mv	AT levmikhaylovichbershteyn hormonalmetabolicandgeneticpredictorsofmetforminefficacyinpatientswithdiabetesmellitusandcancer AT dmitriyalexeevichvasilev hormonalmetabolicandgeneticpredictorsofmetforminefficacyinpatientswithdiabetesmellitusandcancer AT aglayagennadievnaievleva hormonalmetabolicandgeneticpredictorsofmetforminefficacyinpatientswithdiabetesmellitusandcancer AT tatianaevgenevnaporoshina hormonalmetabolicandgeneticpredictorsofmetforminefficacyinpatientswithdiabetesmellitusandcancer AT evgenynaumovichimyanitov hormonalmetabolicandgeneticpredictorsofmetforminefficacyinpatientswithdiabetesmellitusandcancer
_version_	1718429570768568320

Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer

Ejemplares similares